Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell Pathways

Informazioni relative al progetto

ACHILLEUS

ID dell’accordo di sovvenzione: 101058224

DOI

10.3030/101058224

Progetto chiuso

Data della firma CE 5 Aprile 2022

Data di avvio 1 Novembre 2022

Data di completamento 30 Aprile 2026

Finanziato da

• The European Innovation Council (EIC)

Costo totale

€ 2 433 125,00

Contributo UE

€ 2 433 125,00

Coordinato da

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Germany

Periodic Reporting for period 1 - ACHILLEUS (Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell Pathways)

Periodo di rendicontazione: 2022-11-01 al 2023-10-31

Sintesi del contesto e degli obiettivi generali del progetto

Colorectal cancer is one of the most frequent cancers with a high burden on society. Hundreds of thousands of people are diagnosed each year with colorectal cancer. Despite available treatments, the survival of patients with advanced-stage colorectal cancer is poor. Stemness of neoplastic cells has been proposed as a major factor in treatment resistance and high relapse rates, however, drugs targeting stem cell signaling pathways in cancer are still lacking today. The EU-funded ACHILLEUS project aims to develop and validate a novel drug discovery platform that involves patient-derived organoids (PDOs) and phenotypic machine learning-assisted validation to identify therapeutics to target colorectal cancer stem cell signaling pathways. Researchers will target colorectal cancer stem cell signaling pathways to shift the balance between stem cells and differentiated cells, using the targeting of the Wnt pathway as a proof of principle. The goal is to create a new company based on a phenotypic drug discovery platform for targeting cancer stem cell signaling.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

So far, the ACHILLEUS team has developed a novel assay to measure stem cell signaling activity in cultured human cells. In parallel the team optimized the screening platform using patient-derived organoids (PDOs). This comprises both, the work with PDOs in the laboratory and the analysis of complex phenotypic images of PDOs in dedicated data analysis pipelines.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

On the business development side, the ACHILLEUS project was presented at several occasions and started to network with relevant groups of people. A business plan was set up and the IP strategy was further refined.